Method for constructing model of treating triple negative breast cancer with ulinastatin

A technology of triple negative breast cancer, ulinastatin, applied in the field of breast cancer treatment

Inactive Publication Date: 2016-09-07
孙治君
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] 3) Ulinastatin combined with taxotere inhibits the proliferation and metastasis of breast cancer, which may be related to the regulation of CD4+CD25+Foxp3+T / CD4+T in the microenvironment of breast cancer
[0008] At present, there is no report about the fact that ulinastatin may inhibit the secretion of CCL22 by tumor cells, reduce the expression of GITR on the surface of Treg, inhibit the number and function of regulatory T cells in the microenvironment of triple-negative breast cancer, and control tumor growth and metastasis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for constructing model of treating triple negative breast cancer with ulinastatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0038] In order to further understand the content, features and effects of the present invention, the following examples are given, and detailed descriptions are given below with reference to the accompanying drawings.

[0039] Through the present invention:

[0040] 1) Compatibility of ulinastatin with cyclophosphamide or taxotere can inhibit the proliferation of breast cancer cell MCF-7 / DA-MB-231, the mechanism may be related to the reduction of immune and inflammatory factors TNF-a, IL by ulinastatin -6 and IL-10 expression are related to the regulation of immune microenvironment.

[0041] 2) Both ulinastatin and taxotere can significantly inhibit the invasion and metastasis of breast cancer cell MDA-MB-231, and ulinastatin can enhance the inhibitory effect of taxotere, and the mechanism may be related to the down-regulation of VEGF-C, EGFR, The expression of AKT and TGF-β is related to the inhibition of angiogenesis and epithelial-mesenchymal transition, and is also relat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for constructing a model of treating triple negative breast cancer with ulinastatin. The method for constructing the model comprises the following steps: constructing a TNBC (triple negative breast cancer) cell model of CCL22 over-expression and knockdown; constructing a mice tumor-bearing model by virtue of 4T1 cells of CCL22 over-expression and knockdown; and constructing a mice transplantation tumor model by virtue of the 4T1 cells. Meanwhile, the invention discloses a method for detecting influence and mechanism of the ulinastatin on treating the triple negative breast cancer, wherein the method comprises the following steps: detecting inhibition of the ulinastatin on the amount of chemotactic factors CCL22 secreted by TNBC cells; detecting recruitment of the CCL22 on treg cells around the tumor cells; and detecting the expression of GITR on the surface of the treg cells. The research of the invention on the therapeutic value of the ulinastatin on treating the breast cancer is the first case at home and abroad; and the research on the mechanism of the drug affecting tumor microenvironment can offer an application basic research for the clinical application of the drug in the treatment of the breast cancer, in particular the treatment of the triple negative breast cancer.

Description

technical field [0001] The invention belongs to the field of breast cancer treatment, and in particular relates to a method for constructing a model of ulinastatin for treating triple-negative breast cancer. Background technique [0002] The inventor finds through previous research work: [0003] 1) Ulinastatin inhibits breast cancer cell proliferation and promotes cell apoptosis, and its mechanism may be related to ulinastatin reducing the expression of immune / inflammatory factors TNF-a, IL-6 and IL-10 and regulating the immune microenvironment. [0004] 2) Both ulinastatin and taxotere can significantly inhibit the invasion and metastasis of breast cancer cell MDA-MB-231, and ulinastatin can enhance the inhibitory effect of taxotere. The mechanism may be related to down-regulating the expression of TGF-β, inhibiting Angiogenesis and epithelial-mesenchymal transition are related, and at the same time, it is also related to ulinastatin down-regulating the expression level o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/13A61K38/57C12Q1/68C12Q1/02G01N33/68G01N33/574
CPCA61K35/13A61K38/57C12Q1/6886C12Q2600/136G01N33/57415G01N33/68G01N2500/10
Inventor 孙治君陈建生高峰赵晓亮罗杰钟彪王宏王宁孙昕
Owner 孙治君
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap